Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

CRDF Stock  USD 2.61  0.07  2.76%   
Roughly 68% of Cardiff Oncology's investor base is looking to short. The analysis of the overall investor sentiment regarding Cardiff Oncology suggests that many traders are alarmed. The current market sentiment, together with Cardiff Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Cardiff Oncology stock news signals to limit their universe of possible portfolio assets.
  
Cardiff Oncology, Inc. , a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.

Read at finance.yahoo.com
Yahoo News
  

Cardiff Oncology Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Cardiff Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Cardiff Oncology Fundamental Analysis

We analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Cardiff Oncology is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Cardiff Oncology Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cardiff Oncology stock to make a market-neutral strategy. Peer analysis of Cardiff Oncology could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics with similar companies.

Peers

Cardiff Oncology Related Equities

CUECue Biopharma   11.93   
0%
100.0%
LYRALyra Therapeutics   10.53   
0%
88.0%
RVPHReviva Pharmaceuticals   8.77   
0%
73.0%
NLSPNLS Pharmaceutics   3.36   
0%
28.0%
LTRNLantern Pharma   3.22   
0%
26.0%
RNAZTranscode Therapeutics   2.94   
0%
24.0%
CGEMCullinan Oncology   2.75   
0%
23.0%
PDSBPDS Biotechnology   1.86   
0%
15.0%
KODKodiak Sciences   1.83   
0%
15.0%
BOLTBolt Biotherapeutics   1.59   
0%
13.0%
AUTLAutolus Therapeutics   1.53   
0%
12.0%
DAWNDay One   1.53   
0%
12.0%
MREOMereo BioPharma   1.40   
0%
11.0%
CGTXCognition Therapeutics   2.44   
20.0%
0%
INABIn8bio   3.23   
27.0%
0%
SLSSellas Life   3.42   
28.0%
0%
RVPHWReviva Pharmaceuticals   4.35   
36.0%
0%

Complementary Tools for Cardiff Stock analysis

When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data